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Abstract: To further enhance chimerism, 229 
primary allograft recipients have received perioper-
alive intravenous infusion of a single dose of 3 to 
6 X 108 unmodified donor- hone marrow (BM) 
ceUslkg body weight. In addition, 42 patients have 
heen accrued in a concurrent protocol involving 
multiple (up to three) sequential perioperative infu-
sions of 2 X 108 BM cells/kglday from day 0-2 
posttransplantation (PTx). Organ recipients (n = 
133) for whom BM was not available were moni-
tored as controls. The infusion of BM was safe and 
except for 50 (180/0), all study patients have opti-
mal graft function. Of the control patients, allo-
grafts in 30 (23%) have heen lost during the course 
of follow-up. The cumulative risk of acute cellular 
rejection (ACR) was statistically lower in the study 
patients compared with that of controls. It is inter-
esting that, 62O/c of Bolf-augmented heart recipients 
were free of ACR (Grade 2= 3A) in the fust 6 months 
PTx compared to controls. The incidence of oblit-
erative hronchiolitis was also statistically lower in 
study lung recipients (3.8o/c) compared with the 
contemporaneously acquired controls (31 %). The 
levels of donor cell chimerism were at least a log 
higher in the peripheral blood of majority of the 
study patients compared with that of controls. The 
incidence of donor-specific hyporeacth;ty. as deter-
mined by one-way mixed leukocyte reaction, was 
also higher in those BFf-au~ented liver, kidney. 
and lung recipients that could be evaluated com-
pared to controls. J. Leukoc. Bioi. 66: 310-314: 
1999. 
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INTRODUCTION 
Billingham. Brent. and \h·dawar [1] first documented the 
induction of donor-specific tolerance (OST) to transplanted 
allografts in rodents. In human recipients of bone marrow (B\1 I. 
this outcome was first documented by 'lathe et al. [2] in 1963. 
However. despite these earlier obser..-ations. the acceptance of 
organ allografts still remained an enigma. The persistence of 
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donor leukocytes (i.e. chimerism) in the tissues of long-term 
functioning organ allograft recipients prompted us to conclude 
that these cells may playa seminal role in graft acceptance [3, 
4]. This hypothesis is supported by the observation that. similar 
to that of microorganisms. rejection or acceptance (tolerance) of 
transplanted allografts may be governed by the migration and 
localization of the antigen [5]. The idea of this trial came from 
the realization that the BM-derived leukocyte component of 
whole organs (commonly called passenger leukocytes) begins to 
migrate ubiquitously within a few minutes after transplantation 
and that these donor cells survive and constitute a small second 
cell population that is capable of defending itself against the 
immunological system of the recipient [3, 4, 6]. We have 
postulated. in what has been called the two-way paradigm. that 
the eventual induction of mutual nonreactivity of the co-
existing cell populations, each to the other. is the essential 
basis of allograft acceptance [3, 4, 6]. Based on these earlier 
findings. it was therefore hypothesized that. if successful. 
adjuvant perioperative infusion of donor BM to organ allograft 
recipients would culminate (in a relatively higher number of 
patients) in the induction ofDST resulting in reduced incidence 
of acute cellular rejection (ACR) and chronic rejection (CR). 
and would allow early weaning and/or withdrawal of nonspecific 
immunosuppression (IS). 
MATERIALS AND METHODS 
Patients and BM infusion 
-\fler oblainlng inform",\ eon'enl. palienb wilh ,.",\·-Idge organ railur .. who haJ 
no e\"idt>nl'e of aeti\'e infection. disseminat.:t1 malignancy. or prefitnanl'\ wt'rt-' 
\Lbrevialiuns: l~qK donor-specific lol .. rane .. ; B\1. bone marrow; ACR. dl'Uh> 
l't'llular rt'"Jt"ction: CR. chronie rejection: [S. imrtlUllo:--uppression: Tx. tram;.pan-
tal.on; P1'x. posttransplanlalion; "'B. n·rt~bral b"di .. ,; PBL. periph .. ral blood 
l"ukul'l"le,; peR. pohrn .. ras~ chain reacllOn; \ILR. III1X .. J I"mpho<:\w r .. a"l.on; 
LOA. limilin~ dilulion a"av<; G\'HO. grafl-,· .. rsu,-host diseas .. ; yf~lcK mul-
tiple ",slem orltan failure; POD. post-operaliv" da,; OB. oLlileraliw bronchlOl-
ilis; PTLO. p'bllransplant kmphoprolir .. rali, .. di, .. ase; E8 .... Epskln Bdrr 
,irus; O:'H. donor-specific h'·poreacli,il\'. 
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arcruffi into thi, study. In the protocol mandating single penoperati"e 
incK·ulation. 3 to 6 X lOS unmodified donor B\' cellslkg bod, ... eight ... ere 
mfu;.ed intra,enoush into 229 recipient, of li,er In = 71). kidne, In = 8.,)). 
heart In = 27). lung In = 19). small bowel In = 23). and multi-organ In = 41 
tran"plantation IT x \. In addition. in a concurrent protocol. 42 recipients of liver 
In = 61. kidne, In = 28). heart In = 3). and lung In = .5) allografts recein-d 
multiple infu,ion, 12 X lOS donor B~ cellslkg bodv w"ightlda'I of donor BM 
from cia' 0-2 posltransplantation IPTx) .. \s conlemporaneou, controls. 133 
reCipients of liver In = 33). kidne, In = 471. heart ITI = 23). lung In = 121. 
,mall bowel In = 161. and multi-organ In = 21 were also accruffi. These were 
patlt'nts for whom B~ cells were not a"ailable due to our inabIlII' to obtain 
con,.,.nt to retne,e ,ertebral bodies I\'BI from prospecti"e dlmof>'. Recipient 
,"X Imale/female ratiol. follow-up. age at transplant. human l"u\;.oc·'1e antigen 
dispant'. and olher demographic parameters were comparable in patients in the 
stud, IB\l-augrn"nl<·dl and the control groups. BM cell, were har\'ested from 
the \B of the cada"enc donor;; bv a method de,crib"d pre\loush [6J. 
Immuno,uppre"ion wa< with tacrolimus and steroid: CelICept "a, adminis-
terffi to .53 stud, and 17 control patient;.. For steroid-resistanee ACR. an 
antHh'mlK'vte monoc'lonal antibodv IOKT31 WdO used. \0 induction therap' 
wa". emplo,ed. 
In vitro monitoring 
Delamination of chimerism 
Genomic D\A wa;. isolated from recipient', peripheral blood leukocvte, IPBLI 
",th a I)l.\amp Blood Kit (Qiagen Inc .. !'anla Clarita. CAl and quantitatt'd 
'pt'Ctrophotometriealh. 0\.\ samples with OD'''''2H11 1.7-1.9 "prl' used for 
pohmerase chain reaction (PCR) amplifications. A )'-chrom""ome specific 
marker I Sty !(ene I was amplified using the following external primer pair~ in the 
fir;t round of PCR: SRY5.1. 5-GAATAITCCCGCTCTCCGG.\-3: SRY 3.1. 
.)-Gnc.\ACCTGITGTCCAGIT-3 [7]. The amplified product [~OP base pain-
IbplJ "as subjected to a second round of PCR containing the following nest,.d 
primers: SRYS.3. 5-CAGTGTGAAACGGGAGAAAACAGT-3: SRY3.3. 
.5-CITCCGACGAGGTCGATACITAT A-3 [81. To avoid false-negative out-
comes. the qualih' of genomic DNA was controlled b, effective amplification of 
an .\Iu sequence using Al. 5-GGCACTITGGGAGGCCA.\GG-3: A2 . 
.5-T.\C.\AGCITGTGCCATGCCCAAC-3 prime,." [91. For semi-quantitation. 
products of nested PCR (270 bp) were electrophoresed on 1.5,* agarose gel and 
stamffi with SYBR Green I (fMC BioProducts. Rockland. MEl. To determine 
band fluorescence. the gels were scanned on Flourlmager (Mole<'ular Dynam-
ICS. !'unnyvale. CAl and the band volume was quantitated bv placing a 
rectangle around each band with the use of the ImageQuant program. Samples 
of female DNA (500 ngl artificialf~D spiked with increasing quantities ElKlll~ 
0 . .5 n~1 of male D:,\A wen- used (Fig. lA) to obtain a standard curve IFig. IB). 
The quantit,· of donor Imale) D\A in test samples was determined b,' 
comparing its band volume with the standard curve and a ratio of donor! 
recipient DNA was calculated: the levels of donor cell (chimerism) in each 
patient were subsequently deduced. 
riK~d leukocne reaction (MLR) 
Pre- and senall\' posllransplant (everv other month) monitoring of recipient's 
immune status was carried out bv evaluating the proliferative responses of their 
peripheral blood mononuclear cells (PBMCs) to mitogens (concanavalin A. 
phy1ohema~glutininFK r,.call antigens itetanus toxoid). MLR. and limiting 
dilution assav, I LOA). These assays a' well a. detailed studies of most of thes!' 
same patients have been described elsewher,. [6. 10]. 
Statistical analysis 
io~ rank and Fisher's exact test were used for statistical analysis. 
RESULTS 
Clinical outcome 
[\('ept for that in liver allograft recipients. both single and 
multiple infusion of unmodified donor BM cells was safe. 
However. unlike single infusions. multiple infusions of BM 
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resulted in clinical manifestation of severe graft-versus-host 
disease (GvHD: grade III) in 1/6 07%) liver transplant 
recipients: this patient ultimately succumbed to multiple 
system organ failure (MSOF) on postoperative day (POD) 147. 
The increased risk of morbidity and mortality of multiple BM 
infusions in liver transplant recipients has prompted the 
tennination of this protocol in this particular group of patients. 
Patient and graft survival and graft function were comparable in 
study and control groups; allografts in 50/271 (18%) study and 
30/133 (23%) control patients were lost during the course of 
their follow-up. For patients who were ~1O months PTx. the 
dose of tacrolimus and steroids required to maintain a rejection-
free state was lower in BM-augmented (6.4 :!: 3.9 and 5.8 :!: 3.3 
mg/day. respectively) compared with that of controls (7.1 :!: 5 
and 6.2 :!: 3.7 mg/day. respectively). In addition. a slightly 
higher number of study (64o/c) patients have been taken 
off-steroids compared with the controls (59%): none of these 
findings. however_ approach statistical significance. 
Rejection 
The incidence of ACR was statistically lower in the stud\' 
patients compared with controls [F4rure 2: P = 0.0372 (Jog 
rank I]. It must be emphasized that during a comparable period 
of follow-up. the recipients of multiple infusion had a much 
lower cumulative risk of ACR (5-t'H I compared with those 
recei"ing either single infusion or none at all (controlsl. This 
:salutary ('ffect of BM augmentation wa,. more pronounced in 
heart allograft recipients. Sixty-two percent of study patients 
Sa/gar el aL. Infusion of donor leukotD~·teU and toleranee 311 
100 
-~ :.. 80 
= 
.: ,. -,,-------------
K~ 
" 60 :z: , 
p = U.0372 (Log Ronk) 
... , 
: , 
"" '" i -10 
" K~ 
" -;
20 E 
= 
'-' 
0 
6 
Time Post Transplantation (years) 
Fi8. 2. Cumulative risk of acute cellular rejection in BM augmented Ida.;hed 
lines) and contemporaneouslv acquired non-augmented Icontrol) organ allograft 
recipients tsolid lines). BY! augmented. n = 271: controls. n = 133. 
were free of .\CR (grade ~PAF in the first 6 months PTx 
compared with the controls (18%: P = 0.006: Fisher's exact 
test): this beneficial effect was sustained during the course of 
follow-up (> 18 months PTx). The incidence of steroid-resistant 
.\CR (which required OKT3 treatment for its resolution). was 
also lower in the study (6.7%) patients ('ompared with the 
controls (8.69d. It is interesting that. despite having an 
analogous incidence of .\CR. that of obliterative bronchiolitis 
(OB) was statistically lower in the BM-augmented lung allograft 
recipients (1126: 3.8lk) compared with contemporaneously 
acquired controls H.f13: 31 %). 
Incidence of posttransplant Iymphoproliferative 
disease (PTLD) in Epstein-Barr virus-positive 
(EBV+) - EBV- BM recipients 
There was some concern that adjuvant infusion of donor B~f in 
EBV+ --+ EB\' - urgan transplant recipients Olav increase both 
the incidence and the ,;everity of fYI'LD. thus obviating the 
beneficial effect of this therapy. The incidence of clinically 
proven PTLD in adult EB\"- --+ EB\"- B~1-augmented t22 C7[) 
,.llId control (209c) organ transplant recipients was found to be 
comparable ITable II. h is interesting that none of the 
pediatric EB\ _. --+ EBY - BM-augmented organ allograft 
recipients de\elopeJ PTLD. On the contrary. 2/2 (lUO'7c) 
concurrentl~ acquired pediatric controls \\t're diagnosed \\ ith 
this lesion: one died due to MSOF perhaps as a consequence of 
disseminated refractory PTLD (Table 1). Among the adult organ 
allograft recipients. refractory PTLD was not encountered in the 
EBV+ --+ EBV- controls. whereas 2/5 (40%) study patients 
developed a refractory lesion that was unresponsive to initial 
weaning and/or withdrawal of IS (Table 1). In one patient. this 
lesion resolved after immunotherapy with autologous lympho-
kine-activated killer cells: disseminated PTLD leading to 
MSOF was presumed to be the cause of death in the other 
patient (Table 1 l. 
Donor cell chimerism 
As reported previously [6], BM-augmented patients had much 
higher (-92%) incidence of chimerism in their PBL compared 
with controls (-50%). This finding was consistent o\er the 
course of serial follow-up. Similarly. using semi-quantitative 
PCR, the levels of donor cell chimerism were found to be at 
least a log higher in the majority of the evaluated (male --+ 
female Tx recipients) BM-augmented patients compared with 
the controls. It is interesting that, as compared to single. 
multiple perioperative infusions of donor BM were associated 
with further elevation of levels of serially detennined chime-
rism in the PBL of organ allograft recipients. 
In vitro immune reactivity 
To undertake comparative anal~·sisK one-way MLR was per-
fonned serially PTx only in organ allograft recipients from 
whom pre-transplant blood was procured and donor splenocytes 
were available. [sing a previously outlined criterion [10]. 
higher incidence of donor-specific hyporeactivity (DSH) was 
encountered in those liver. kidney. and lung transplant recipi-
ents that were evaluated in this study compared with the 
controls (Table 21. On the contrary, comparable levels of donor 
and third party-specific (data not shown) hyporeactivit\ were 
witnessed in stud~D and control heart. small bowel Idata not 
~ho ..... n), kidney + pancreas, and multi-organ transplant Idata 
not shown) recipients (Table 2). 
DISCUSSION 
The commonality between the body's immune responses against 
transplanted organ allografts and infections has long been 
recognized [II]. This hypothesis received major impetus when 
it was documented that. similar to that of Tx alloantigens. 
T\BLE l. TIlt' [n.-"len('!:" (}j·Clinica[h aiagno~ ... d Post-transplant L\mphoprolif .. ratiH' Dis .. ,,,,, ano Its Outcome in B\'-augmented and Control 
Organ Transplant Re('ipients 
un - - EH\ - l~y .. I .. ~d Rt"'rra(·tl'r. 
P.Jlit"nts n' tr .in:-pL.mI:" 1 n: (11 I'TLD I'ruy Clinl(:al'lutt'ume 
B\I-.-\ugmented 
\dult 209 2:3/209 II [ '7c) S12:3 ;22'1-) 2/5 (-lO'k) Resoht'd in one patlt'nt with L\l\ eell therapv: 
the oth .. r patient died of \lSOFd 
Perliatric 1:- 6117 n,'J'7c) O/610''() \.\c \\' 
Control 
.\dult [09 .')Il t)9 t ,'J'7c1 liS 120<7c) 011 to'7c) \.\' 
Pediatne It 21ll t18'7c) 2/2 t LOO<7c) 112 (50'7c) Died due to \lSOFd 
• Patients with known EB\· status before transplant. ; r nresponsi,,, to reduction and/or withdrawl of immunosuppression. ,. \ot applicable. J Vlul • 
tiple S',Hem organ iatlure possibh due to disseminated PTLD. 
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TABLE 2. The Incidence of Donor-Specific Immunomodulation in 
Bone Marrow-.l.ugmented and :'lion-Augmented Organ Transplant 
Recipients in "'hom In lltro Immune Monitoring was r easible 
lmmuflt' ",talus I n cCY Ii 
EF~an I"pt· Hypo ..... inlf'rmM/iatf' Rt"acli\t' 
Liver 
B\I augnwnted I:,inpe infusion 1 36 18 15()l/( 1 I8150'7cl 
B\t augmented 1 multiple infusionl 3 2 166lfl) II33lfl ) 
B\t non-augment('(1 ]8 .t 122lfl) J.l (77lfl 1 
K;dnel 
8,\1 augmented Ising:le infusion I 21 1517]'7<1 6128lfl) 
B\I augmented Imultiple infusion 1 5 21.w<K1 316O'k) 
8\1 non-augmented 13 5 (38lfl) 816Io/c) 
I\.idnpy + Isld, 
B\I augmented I"inpe infusion 1 5 2(4Olfl) 3 160o/c) 
B\I augmented IIllultiple infusion) I tlOO'7c) 
8\1 non-aug:nwnt('(j ItIOOlfl) 
I\.idnt'l + Pancrf'a;; 
8\1 augmented I"ingle infusion I 29 I21.l]lfll 17158lfl ) 
B\I augmented Imultiple infusion) 10 2(2Olf() 818Oo/c) 
8\t non-augmented II .l (36lfl ) 71M'7cl 
Heart 
B\1 augmented tsingle infusion I 16 31l9'7r ) 13 (81lfl) 
8\1 augmented ImultipJe infusion I 2 0 2 1100lfl) 
8\1 non-augmented ]3 2 il5'7r1 II (84lfl) 
Lungs 
B\I augmented 8 5162lfl ) 3 (37'7c) 
8M non-augmented 5 2 (4(I'H) 316O'k) 
acquired immune responses against infectious agents were also 
MHC-restricted [12]. Because migration and localization of 
antigen was evidenced in both types of immune responses, it 
has been argued that in an otherwise naive host. this may be the 
seminal event resulting in the long-term acceptance of the 
allografts as well as the eradication of pathogenic infectious 
agents [5]. After T x, migration of alloantigens from the graft into 
the host's lymphoid and non-lymphoid tissues has been un-
equivocally demonstrated in long-term kidney and liver trans-
plant recipients [3, 4]. The role of these ubiquitously localized 
donor cells in the induction of DST has been corroborated in 
numerous pre-clinical models of Tx tolerance [13-15]. Al-
though the precise phenotype of these migraton' cells is as yet 
unknown, it was, however. determined that they were CD45+ 
cells of donor B\1 origin [3. 4, 13-15]. Accordingly, it was 
proposed that willful augmentation of this phenomenon in organ 
allograft recipients by perioperative infusion of BM cells 
obtained from either ('adaveric or living related donors. would 
greatlv reduce the incidence of ACR and CR as well as allow 
early weaning and/or withdrawal of nonspecific IS 13. 4. 6]. 
In 1992. we initiated a prospective elinical trial to affirm or 
refute this hypothesis in recipients of various organ allografts. 
To replicate the natural events that predictably transpire 
perioperativeiy, the recipients were not conditioned and the 
infused BM was not modified. Due to ethical and fiscal 
('on('erns. this study was not randomized: ayailability (or 
otherwise) of YB from cadan'ric donors determined the accrual 
of a prospective recipient as a study or a control patient. Except 
for recipients of li\'er allografts. the infusion of single or 
multiple doses of donor B" was safe. In the liyer recipients. 
however. the perioperative infusion of multiple (but not single) 
doses of BM was associated with increased incidence of morbid 
G,·HD. thus prompting precocious termination of this latter 
protocol. To preyent untoward complications (with the excep-
tion of the first six lil"(:'f recipients). recipients of supposedly 
leukocyte-rich organs (i.e .. small howel. liYer. or multi-
yiscerall. receil'ed only a single holus infusion of donor BM 
immediately after organ Tx. On the contra~·K since l.pril 1996. 
recipients of all other organs han' receiyed multiple infusion!' 
of donor BM on 3 consecuti,e days (day 0-2) PTx. 
During the course of follow-up. slightlY higher patient and 
graft loss has been documented in the control group compared 
with that of the study.l. !though being monitort-d. these 
parameters are not prima~D end-points of this study: the large 
number of patients that need to be acquirf'd in each organ group 
to conduct appropriate statistical analy"is is con"idered prohibi-
tile .. \5 predicted. the cumulative risk of deyeloping .l.CR was 
~tatiRtiEDally lower in the B'I-augmented patients compared 
with the controls. It is interesting that this risk was lowered 
further in recipients of multiple BM infusion in whom corre-
spondingly higher levels of donor cell chimerism were docu-
mented. Although admiHedl! longer {nHl}\\ -up is required to 
confirm this finding. it ne\·ertheJe.'i" .'iUppNts our earlier 
assf'rtion that establishment of stable ('himerism would result 
tin the majority of the patients) in the induction of DSH [3,4.6]. 
This benign effect of B\l infusion is perhaps best exemplified in 
heart allograft recipients in whom. d~plte reien,ion of donor-
specific in l:itro immune reactivity. the incidence and severity 
of ACR was markedly lower in study patients compared with 
controls. Because an increased incidence of ACR is considered 
a precursor to the eventual evolution of CR. it eould be argued 
that BM augmentation would mitigate, if not abrogate. the 
development of the latter lesion in study heart allograft 
recipients. 
In recipients of lung allografts. this predicted outcome has 
already been realized. Despite analogous incidence and sever-
ity of ACR, that of OB is remarkably lowt-r in patients in the 
study group compared with that of the controls. It is interesting 
that, when evaluated serially, BM-augmented lung recipients 
exhibited a higher incidence of DSH compared with the 
controls. Correspondingly, in those who are ;::: 1 year PTx, a 
higher number (l9o/c) of B\1-augmented lung allograft recipi-
ents have been taken off steroids as compart-d to the concur-
rently ace-rued controls (l19c l. 
In coneiusion. infusion of donor BM was safe. with resultant 
increase in both the incidence and the levels of chimerism in 
the peripheral blood of organ allograft recipients. This latter 
finding translated into marked reduction in the incidence of 
ACR and CR with induction of DSH in BM-augmented liver. 
kidney. and lung recipients. l'nlike that in rodents and/or 
non-human primates. it is our contention that much longer 
follo\\-up would be required to realize the entire spectrum of 
predicted t-ffican of deliberate BM augmentation in human 
organ allograft re(,ipients. In light of our previous experienct- of 
deliberateh wt-aning IS (161, we have initiatt-d a similar 
prospectiye trial in BM-augmented and non-augmentt-d liver 
allograft recipients who exhibit stable graft function and are ;:::5 
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years PTx. It is our assertion that experience acquired from this 
latter study would ultimately assist us to possibh .... ean and/or 
withdraw nonspecific IS in recipients of other organ allografts. 
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